Cargando…

CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation

PURPOSE: Liver transplantation is the treatment of choice for patients with end-stage liver disease. Due to the between- and within-individual pharmacokinetic variability in tacrolimus, used to prevent rejection after transplantation, it is difficult to predict the dose needed achieve the target lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Eunhee, Kim, Myeong gyu, Oh, Jung Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207397/ https://www.ncbi.nlm.nih.gov/pubmed/30498355 http://dx.doi.org/10.2147/TCRM.S184376

Ejemplares similares

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism
por: Wan, Ping, et al.
Publicado: (2022)

Generic Tacrolimus (Tacrobell(®)) Shows Comparable Outcomes to Brand-Name Tacrolimus in the Long-Term Period After Adult Deceased Donor Liver Transplantation
por: Kim, Jong Man, et al.
Publicado: (2019)

Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients
por: Kim, Jae Hyun, et al.
Publicado: (2019)

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
por: Guo, Zhe, et al.
Publicado: (2023)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
por: Kim, Hyeyoung, et al.
Publicado: (2014)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
por: Mendrinou, Effrosyni, et al.
Publicado: (2020)

Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation
por: Chen, Yi-kuan, et al.
Publicado: (2014)

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantation
por: Huang, Li, et al.
Publicado: (2021)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype
por: Itohara, Kotaro, et al.
Publicado: (2019)

Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients
por: Raj, T. Yashwanth, et al.
Publicado: (2022)

Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
por: Sohn, Minji, et al.
Publicado: (2018)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Using Tacrolimus in Living Donor Liver Transplantation Recipients with High Model for End-stage Liver Disease Scores Might Increase the Risk of Postoperative Neuropsychologic Deficits
Publicado: (2013)

Pyrosequencing to Identify Homogeneous Phenomenon When Using Recipients/Donors with Different CYP3A5*3 Genotypes in Living Donor Liver Transplantation
por: Chiu, King-Wah, et al.
Publicado: (2013)

Capability of Utilizing CYP3A5 Polymorphisms to Predict Therapeutic Dosage of Tacrolimus at Early Stage Post-Renal Transplantation
por: Niioka, Takenori, et al.
Publicado: (2015)

Postoperative Health Status and Quality of Life After Pure Laparoscopic Donor Hepatectomy for Living Donor Liver Transplantation
por: Cho, Chan Woo, et al.
Publicado: (2022)

Individualized Dosage of Tacrolimus for Renal Transplantation Patients Based on Pharmacometabonomics
por: He, Xiaoying, et al.
Publicado: (2022)

Author Correction: Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients
por: Sohn, Minji, et al.
Publicado: (2020)

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
por: Kim, Jong Man, et al.
Publicado: (2020)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
por: Sapisochin, Gonzalo, et al.
Publicado: (2022)

Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
por: Chiu, King-Wah, et al.
Publicado: (2013)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Infections after Living Donor Liver Transplantation in Children
por: Kim, Jeong Eun, et al.
Publicado: (2010)

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients
por: Wu, Zhengshan, et al.
Publicado: (2013)

Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation
por: Han, Nayoung, et al.
Publicado: (2017)

Living donor liver transplantation /
Publicado: (2007)

Clinical and laboratory postoperative impact on outcome of living donor liver transplantation recipients
por: Nassar, Y, et al.
Publicado: (2013)

Sarcopenia adversely impacts postoperative complications in living-donor liver transplantation recipients
por: Wu, Mei-Yun, et al.
Publicado: (2021)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Liver Transplantation for Metabolic Liver Disease: Experience at a Living Donor Dominant Liver Transplantation Center
por: Kim, Jun Suk, et al.
Publicado: (2015)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

The International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline
por: Miller, Charles M., et al.
Publicado: (2017)

Days alive and out of hospital and graft survival after living donor liver transplantation
por: Oh, Ah Ran, et al.
Publicado: (2023)

Early postoperative weight gain is associated with increased risk of graft failure in living donor liver transplant recipients
por: Jeong, Hye-Won, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1vlu0ql0dmidv1vc4bds3cfh0t